CD274 and non-small cell lung carcinoma: Meanwhile, immune checkpoint inhibitors (ICIs) targeting programmed death receptor‐1 (PD‐1) and programmed death receptor ligand‐1 (PD‐L1) also achieved advanced NSCLC.